# Shelter Pharma (NSE: SHELTER) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SHELTER · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹46 Cr, it ranks 3125th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 11.8% in FY26. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹28 Cr (−4.9% year on year) and net profit ₹0 Cr (−90.1%), on a consolidated basis. Promoters held 44.38% of the company as of 14 May 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹46 Cr |
| ROE | 11.8% (FY26) |
| ROCE | 16.0% (FY26) |
| Debt to equity | 0.01 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹28 Cr | −4.9% | ₹0 Cr | −90.1% | ₹0.03 |
| Q4 FY26 | ₹34 Cr | +0.5% | −₹1 Cr | — | −₹0.34 |
| Q3 FY26 | ₹31 Cr | −4.5% | ₹1 Cr | — | ₹0.29 |
| Q2 FY26 | ₹35 Cr | +1.8% | ₹1 Cr | +296.3% | ₹0.40 |
| Q1 FY26 | ₹30 Cr | +2.0% | ₹1 Cr | +170.0% | ₹0.31 |
| Q4 FY25 | ₹34 Cr | +4.6% | −₹0 Cr | −353.8% | −₹0.13 |
| Q3 FY25 | ₹32 Cr | +24.6% | ₹0 Cr | −100.0% | — |
| Q2 FY25 | ₹34 Cr | +23.1% | ₹0 Cr | +145.5% | ₹0.11 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹51 Cr | ₹7 Cr |
| FY24 | ₹40 Cr | ₹6 Cr |

## Shareholding (14 May 2026)

- Promoters: 44.38%
- Non-institutions: 55.62%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Biofil Chemicals & Pharmaceuticals](https://app.pivotnow.in/stock/BIOFILCHEM) | ₹30.00 | ₹49 Cr | 17.5 | — |
| [Shanmuga Hospit](https://app.pivotnow.in/stock/SHANMUGA) | — | ₹48 Cr | — | — |
| [Mangalam Drugs And Organics](https://app.pivotnow.in/stock/MANGALAM) | ₹29.66 | ₹47 Cr | — | — |
| [Amkay Products](https://app.pivotnow.in/stock/AMKAY) | — | ₹46 Cr | — | — |
| [Vista Pharma](https://app.pivotnow.in/stock/VISTAPH) | — | ₹45 Cr | — | — |
| [KMS Medisurgi](https://app.pivotnow.in/stock/KMSMEDI) | — | ₹43 Cr | — | — |

## Questions and answers

### What is the market cap of Shelter Pharma?

Shelter Pharma's market capitalisation is ₹46 Cr (₹46 Cr) at the 22 Oct 2026 close, ranking 3125th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Shelter Pharma?

Return on equity was 11.8% in FY26 and return on capital employed was 16.0% in FY26 (standalone figures).

### Is Shelter Pharma a debt-free company?

Shelter Pharma is close to debt-free: its debt-to-equity ratio was 0.01 in FY26.

### What were Shelter Pharma's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Shelter Pharma reported revenue of ₹28 Cr, −4.9% year on year, and net profit of ₹0 Cr, −90.1% year on year.

### What is the shareholding pattern of Shelter Pharma?

As of 14 May 2026: promoters 44.38%, non-institutions 55.62%.

### Who are Shelter Pharma's competitors?

The listed Pharma & Healthcare companies closest to Shelter Pharma by market cap are Biofil Chemicals & Pharmaceuticals, Shanmuga Hospit, Mangalam Drugs And Organics, Amkay Products, Vista Pharma and KMS Medisurgi.

### Is Shelter Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Shelter Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SHELTER against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.